The combined HR for the eight appropriate studies was 2.17 (95% CI: 1.71–2.77, P < 0.00001), suggesting that TGF-β overexpression was an indicator of poor survival for NSCLC patients (Fig. 2). Here, TGFB1 is linked to non-small cell lung carcinoma.